Post Operative Pain Management Market Size

Post-Operative Pain Management Market Analysis

The Post Operative Pain Management Market size is estimated at USD 40.46 billion in 2024, and is expected to reach USD 53.61 billion by 2029, growing at a CAGR of 5.79% during the forecast period (2024-2029).

The COVID-19 pandemic significantly impacted the postoperative pain management market. As per the April 2022 data published by PubMed, it was observed that people across the United States and Canada suffering from chronic pain witnessed a significant increase during the pandemic. Similarly, according to the study published in the Turkish Journal of Anaesthesiology and Reanimation in June 2022, most pain care centers are forced to close their doors. All outpatient and interventional procedures were reduced due to the government's strict lockdown. Thus, the pain management market was greatly impacted. However, the market is currently recovering well owing to the resumption of surgical procedures and the decline in COVID-19 cases.

Furthermore, the factors fueling the market's growth are the growing number of surgical procedures, the rising number of emergency hospital visits, the increasing demand for non-opioid-based analgesics, and the increasing focus on palliative care.

A growing number of surgical procedures drives the demand for postoperative pain management medications. For instance, according to the Canadian Institutes of Health Information published in June 2022, in 2021, 55,300 hip and 55,285 knee replacements were performed in Canada. Additionally, according to the Organisation for Economic Co-operation and Development data published in April 2023, the number of hip replacement surgeries increased in Turkey from 41,604 in 2020 to 46,368 in 2021. With such a huge increase in the number of surgeries performed across several countries, the market for postoperative pain management drugs is expected to exhibit substantial growth, as these medications play a crucial role in managing the pain caused by surgical procedures.

Likewise, a study published in PubMed Central in January 2022 stated that, according to research conducted by the United States Institute of Medicine in June 2022, postoperative pain was a common but often undertreated disease, with 80 percent of surgery patients experiencing postoperative pain and less than half of these patients reporting appropriate pain control. Furthermore, the study states that, according to a nationwide survey, 39 percent of postoperative patients feel severe to terrible pain. Such unmet needs greatly highlight the need for postoperative pain management drugs to optimize palliative care among the patient population, thereby providing lucrative opportunities to prominent players within the market.

Additionally, strategic initiatives by the market players, such as product launches and research and development activities in the field of pain management, are expected to boost the market's growth. For instance, in April 2022, Assiut University started a trial to evaluate the population pharmacokinetics and pharmacodynamics of rectal dexmedetomidine Niosomesfor postoperative analgesia in pediatric cancer patients undergoing bone marrow biopsy and aspiration in comparison with the intravenous and rectal plain formulation. Additionally, in April 2022, Acadia Pharmaceuticals Inc. announced top-line results from a Phase 2 randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery. The primary endpoint, a comparison of cumulative pain intensity scores over 24 hours between the ACP-044 1600 mg once daily, the ACP-044 400 mg four times daily, and the placebo treatment arms, was not met.

Thus, all aforementioned market, such as the rising number of surgical procedures and strategic initiatives by the market players, is expected to boost the market over the forecast. However, concerns about the overuse of opioids are a major factor restraining the market's growth.